The effect of FGF21 on protecting against NAFLD/NASH is targeted on the pathological characteristics of NAFLD/NASH, including reducing hepatocyte stress and hepatic steatosis as well as directly protecting against inflammation and fibrosis. The gene discussed is FGF21; the disease is metabolic dysfunction-associated steatotic liver disease.